This summary is from the 2015 Prostate Cancer Conference where in his lecture, John Mulhall, MD, discussed Optimizing Sexual Function Outcomes. Dr. Mulhall is preeminent thought leader in sexual side effect treatment. Here is the summary:
Viewing entries tagged
Radium-223 (Alpharadin) A Novel Targeted Alpha-Emitter for Bone-Metastatic Castrate-Resistant Prostate Cancer
Radium-223 (or Alpharadin) is a new targeted alpha-emitting agent which has shown a prolongation of survival in castrate-resistant prostate cancer patients with bone-metastatic disease (5).